(Dis)Trust your gut: the gut microbiome in age-related inflammation, health, and disease

Thomas W. Buford

Abstract

Chronic inflammation represents one of the most consistent biologic features of aging. However, the precise etiology of persistent low-grade increases in inflammation remains unclear. Recent evidence suggests that the gut microbiome may play a key role in age-related inflammation. Indeed, several studies have indicated that older adults display an altered composition of the gut microbiota, and early evidence indicates that this dysbiosis is associated with the presence of several key circulating inflammatory analytes. The present review summarizes knowledge on age-related inflammation and discusses how potential relationships with gut dysbiosis may lead to novel treatment strategies in the future.

Background

In humans, aging is a continual and progressive process that results in decreased physiologic function across all organ systems [1]. These physiologic decrements result in an increased vulnerability to infection and disease that dramatically elevates mortality risk [2, 3]. Compared to persons 25–44 years of age, mortality risk among older adults is elevated by 100-fold for stroke and chronic lung disease, roughly 90-fold for heart disease, pneumonia, and influenza, and over 40-fold for cancer [2]. Given the rapid increase in life expectancy and increasing proportion of older adults within the population [4], an increased understanding of the biologic mechanisms which underlie age-related increases in disease prevalence are warranted.

Aging and inflammation

Though the etiologies of age-related diseases are quite diverse, significant evidence implicates chronic, low-grade inflammation as one of the most consistent biologic features of both chronological aging and various age-related diseases/disorders [5–8]. In fact, a recent PubMed search for the terms “aging and inflammation” revealed nearly 10000 publications in this area (Fig. 1) with this pair of risk factors implicated in the pathobiology of a wide variety of diseases and disorders across nearly every organ system (Fig. 2a).

Inflammation is commonly recognized as a localized response to tissue injury or infection that aids in the repair of damaged tissue and/or destruction of the harmful agent [4]. Classically characterized by pain, heat, redness, swelling, and loss of function, acute inflammation is typically resolved (in healthy individuals) in relatively short order to promote the restoration of tissue function. However, during advanced age, the ability to resolve inflammation becomes impaired leading to sustained tissue infiltration of leukocytes and the chronic release of pro-inflammatory cytokines and chemokines [9]. As a result, the initial local event has long-term systemic consequences.

Indeed, elevations in pro-inflammatory mediators such as interleukin-6 (IL-6), C-reactive protein (CRP), and tumor necrosis factor alpha (TNF-α) have been consistently reported during late adulthood even in the absence of acute infection [10–12]. Though it is unknown if these
inflammatory mediators directly cause adverse health outcomes, chronic low-grade inflammation has been associated with the prevalence of a wide-range of age-related comorbidities—cardiovascular disease [13–15], insulin resistance and diabetes [16–18], osteoporosis [19–21], cognitive decline and dementia [22–24], frailty and disability [25–27], and cancer [28–30]—as well as mortality [31–33].

Though factors such as obesity and insulin resistance, smoking, and changes in circulating sex hormone concentrations have been associated with age-related inflammation [34], the largest contributor to increases in inflammatory mediators has traditionally been thought to decrease in the efficiency of the immune system, i.e., immuno-senescence [6, 8]. Immuno-senescence is characterized by thymus atrophy, reductions in neutrophil function, naïve T cell number, and the cytotoxic capacity of natural killer cells, and lowered B-cell antibody production in response to antigen [35, 36]. The most widely held belief regarding the cause of immuno-senescence is that chronic lifetime antigenic burden exhausts a finite capacity of the organism’s immune system [4, 37, 38]. Therefore, we exchange protection against infection for long-term risks of chronic inflammation and disease [4, 39].

Very recently, however, emerging evidence has suggested that the gut microbiome may play an integral role in these age-related inflammatory changes. Recent evidence indicates that advanced age is associated with changes in microbiota composition characterized by a loss of diversity in the core taxa [40]. Moreover, these age-related changes in the microbiome have also been recently associated with key geriatric syndromes including physical frailty [41] and dementia [42]. Therefore, the objective of this review is to discuss the available evidence related to gut microbiome and aging, with particular emphasis on age-related inflammation and associated diseases/conditions.

The gut microbiome and health
The human intestinal tract (i.e., “gut”) is inhabited by over 100 trillion microorganisms; including over 1000

![Fig. 1](Image) Number of PubMed citations by year using the search term “aging and inflammation”

![Fig. 2](Image) a Prominent health conditions with both biologic age and chronic inflammation as central risk factors. b Prominent health conditions with evidence linking them to gut dysbiosis. Note the similarities between the conditions associated with aging and inflammation and those associated with gut dysbiosis.
species of known bacteria.[43] These organisms have co-evolved with humans over millennia to live together for mutual benefit [44, 45]. Though commonly overlooked in considerations of human health and disease treatment (hence the nickname the “forgotten organ” [46]), gut microorganisms encode >150 times more genes than the human genome and are highly involved in numerous metabolic reactions which influence normal host physiology and metabolism [47, 48]. In fact, an enormous portion of the body’s constitutive immune function is dedicated to maintaining homeostasis with the microbiota, as evidenced by the fact that 70% of the body’s lymphocytes reside in the gut-associated lymphoid tissue [49].

Given the substantial portion of the immune system dedicated to maintaining host relationship with the microbiome, it is perhaps unsurprising that gut microbiota are heavily involved in local inflammatory responses to acute injury and/or infection. Indeed, commensal bacteria are a critical regulator of regulatory immune responses including tolerance—the active suppression of inflammatory responses to food and other orally ingested antigens [50]. In fact, these bacteria are known to play a protective role in acute inflammatory responses to injury at least in part through toll-like receptor (TLR) activation to promote tissue repair and survival [51]. Moreover, immune cells also regulate inflammation in intestinal injury and allergy via recognition of short-chain fatty acids (SCFA) produced via bacterial breakdown of indigestible dietary components such as fiber [52).

Failure to regulate these responses well-established as a contributor to the development of food allergies and/or various inflammatory bowel diseases affecting the gut. More recently, however, it has become apparent that changes to microbial composition and density can alter immunity and inflammation within organs distal from the intestine [53]. For example, the reduction of beneficial gut bacteria via antibiotic treatment has demonstrated impaired systemic allergic inflammatory responses as well as immune responses to viral (influenza) infections [54–56]. Though beyond the scope of the current review, I refer readers to an excellent review by Belkaid and Hand [50] for in-depth discussion of the potential mechanisms underlying microbiota-based changes to systemic immunity and inflammation.

In line with known interactions of the microbiome with the systemic circulation and distal tissues, gut dysbiosis—commonly defined as a disturbance of or change in the density and/or composition of gut microbiota—has been linked to a wide variety of diseases and health conditions (Fig. 2b). These conditions include cystic fibrosis [57], inflammatory bowel conditions (irritable bowel syndrome, Crohn’s disease, and colon cancer [58–60], neurological diseases (Parkinson’s disease, Alzheimer’s disease, and multiple sclerosis)) [61–63], metabolic diseases (obesity and diabetes) [64, 65], as well as musculoskeletal conditions (frailty, osteoporosis, rheumatoid arthritis, and gout) [41, 66–68]. Notably, as evidenced by the remarkable similarity between Fig. 2a, b, the majority of these conditions exhibit age-related increases in incidence. Accordingly, it seems relevant to explore the possibility that age-related inflammation may stem at least partially from changes to the gut microbiome.

**The aging gut microbiome**

As noted above, the human ageing process is associated with gradual declines in function across virtually every bodily organ. In contrast, however, the bacterial organisms in the gut do not age per se and thus might be unexpected to follow the typical trajectory of physiological decline seen elsewhere in the body [69]. And yet, as pointed out by O’Toole and Jeffery [69], older individuals often experience gut-associated comorbidities, changes in diet and physical activity patterns, and other gut-related physiologic changes which may influence gut bacteria. Thus, questions persist regarding how such changes may interact with gut bacteria to influence microbiome composition and function.

Compared to evidence related to aging and inflammation, less is known regarding associations between aging and the microbiome. In fact, in contrast to the thousands of peer-reviewed publications on aging and inflammation, a PubMed search for “aging and microbiome” yielded only 466 results and a search for “aging and dysbiosis” yielded a mere 34. Moreover, only a handful of studies to date have investigated the aging microbiome in humans (Table 1). Still, at least two early studies in this area have documented that advanced age is associated with changes to both the composition and stability of gut microbiota [40, 70]. Biagi et al. reported that a group of centenarian from Northern Italy displayed low species diversity compared to younger adults (~30 years of age). They also noted specific changes within Firmicutes (one of the two dominant phyla commonly found in the gut) subgroups and enrichment of Proteobacteria—a group containing many opportunistic bacteria which can overtake commensal bacteria and induce pathology [70]. These microbiome changes were also characterized by a loss of genes for short-chain fatty acid production and an overall decrease in the saccharolytic potential, while proteolytic functions were more abundant than in the intestinal metagenome of younger adults [71]. Interestingly, these changes in bacterial...
content were also moderately associated with circulating plasma concentrations of inflammatory cytokines interleukins six (IL-6) and eight (IL-8). Surprisingly, however, despite these interesting findings among the centenarians, this group did not find significant differences in microbiota composition between the younger adults and a group of older adults with an average age of 70 years.

In contrast, findings from the Irish ELDERMET cohort [72] did indicate alterations in the core microbiota of persons over 65 years of age. These changes were generally characterized by a greater proportion of Bacteroides spp. and distinct abundance patterns of Clostridium groups compared to younger individuals. Older individuals also displayed a loss of diversity-associated taxa, including Prevotella and associated genera [40, 73], which can contribute to instability in the microbiome composition. However, the authors noted that the variability in the microbiota profiles of the older persons was

| Study                        | Population | Age          | Age-affected microbiota                        | Age effect | Additional details                                                                 |
|------------------------------|------------|--------------|-----------------------------------------------|------------|------------------------------------------------------------------------------------|
| Hopkins et al. (2002) [130]  | British    | 21–34 years  | Bacteroides species diversity                 | ↑          | CDAD patients had greater diversity lactobacilli/clostridia but reduced bacteroides, prevotella, and bifidobacteria |
| Hayashi et al. (2003) [131]  | Japanese   | 79–84 years  | Clostridium rRNA subcluster XIVa               | ↓          | Hospitalized patients displayed age-related changes along with increased proteolytic bacteria no. and diversity |
| Woodmansey et al. (2006) [132]| British    | 19–35 years  | Bacteroides                                   | ↓          | High frailty scores associated with reduced lactobacilli, bacteroides, prevotella no.; increased enterobacteria |
| Van Tongeren et al. (2005) [74]| Dutch      | 70–100 years | N/A                                           | N/A        | Microbiota composition clustered by diet and residence location + significantly correlated with frailty, co-morbidity, and inflammation |
| Biagi et al. (2010) [70]     | Italian    | 25–40 years  | Clostridium cluster XIVa                      | ↓          | Young and elderly showed similar microbiota, while differences observed in centenarians only. |
| Claesson et al. (2011) [72]  | Irish      | 28–46 years  | Firmicutes                                    | ↑          | Hospitalized patients displayed age-related changes along with increased proteolytic bacteria no. and diversity |
| Claesson et al. (2012) [73]  | Irish      | 28–46 years  | N/A                                          | N/A        | Hospitalized patients displayed age-related changes along with increased proteolytic bacteria no. and diversity |
| Rampelli et al. (2013) [71]  | Italian    | 38–102 years | Bacterial DNA gene expression for: short-chain fatty acid production Pathobionts | ↓↑↑↑↑↑↑↑↑↑↑↑ | Long-term care stays and antibiotic use associated with increased alterations in microbiota composition and diversity |
| Jeffery et al. (2016) [40]   | Irish      | 64–102 years | N/A                                          | N/A        | Low microbial diversity associated with greater temporal instability |
| Jackson et al. (2016) [41]   | British/Irish | 42–102 years | N/A                                          | N/A        | Robust associations between frailty and gut microbiota F. prausnitzii negatively associated E. dolichum and E. lenta positively associated |
| Odamaki et al. (2016) [133]  | Japanese   | 0–104 years  | Proteobacteria/Bacteroidetes                  | ↓↑↑↑↑↑↑↑↑↑↑↑ | Gut microbial populations and peripheral inflammatory cytokines associated with cognitive impairment and brain amyloidosis |
| Cattaneo et al. (2017) [42]  | Italian    | Mean ~ 70 years | N/A | N/A | Gut microbial populations and peripheral inflammatory cytokines associated with cognitive impairment and brain amyloidosis |

*Age-effect compared to prior study of young adults; HE hospitalized elderly patients on antibiotics, ^range and overall mean for the full study not reported (reported by study group)*
quite large—making phenotype prediction difficult. Several key factors—particularly diet and the use of antibiotics—were key predictors of these changes in both community-dwelling seniors and residents of long-term care facilities. These factors, diet in particular, could potentially explain differences between findings from the Italian and Irish cohorts. As such, these and other relevant factors necessitate the continued study of the microbiome across populations.

Notably, data from the ELDERMET cohort revealed an interesting potential association with physical frailty as evidenced by differences among older persons living in long-term care and/or rehabilitation facilities compared to community-dwelling peers [73]. These differences were also associated with several systemic markers of inflammation including IL-6, IL-8, CRP, and TNF-α. The association with frailty in the cohort was recently expanded more formally along with concordant findings from 728 female twins enrolled in the Healthy Ageing Twin Study [41]. These findings were similar to those from a prior small cohort of older adults from The Netherlands [74]. Thus, available data suggest that the gut microbiome may play at least some role in the development of physical frailty among the elderly.

Similarly, early findings now suggest that gut dysbiosis may contribute to age-related declines in cognitive function. Cattaneo et al. recently reported that brain amyloidosis and peripheral inflammation among cognitively impaired elders was associated with the abundance of pro- and anti-inflammatory gut microbiota [42]. Indeed, brain amyloid content and circulating inflammatory analytes were positively associated with the inflammatory bacteria taxon *Escherichia/Shigella* and negatively associated with the anti-inflammatory *E. rectale* taxon. To my knowledge, these are the first data directly linking the gut microbiota to age-related cognitive decline, though numerous studies in other models (e.g., Parkinson’s, multiple sclerosis, animal models of Alzheimer’s disease) exist to indicate a well-defined gut-brain axis which could contribute to age-related dementias [62, 75, 76]. Given the dramatic public health implications of understanding and intervening upon age-related dementias, continued research in this area seems highly warranted.

**Etiology of age-related changes in the microbiome**

The precise etiologic explanation for these age-related changes remains incomplete. Across the age-spectrum, dramatic increases in the use of antibiotics and increasing pervasiveness of a high-saturated fat and high-sugar “western” diet are proposed to directly contribute to the depletion of important beneficial components of the microbiome [50, 77]. In turn, these changes contribute to chronic activation of the immune system and a dramatic rise in the prevalence of chronic inflammatory disorders. These two factors also represent key modifiable health factors which may contribute to exacerbated dysbiosis among older adults.

In the United States of America, rates of antibiotic prescription actually dropped from 2000–2010 among children and young to middle-aged adults [78]. In contrast, prescription rates increased among older adults with the most dramatic increases seen among persons ≥80 years of age [78]. Additionally, rates of antibiotic prescription have risen substantially in recent years in residential care facilities [79]. These trends may at least partially explain age-related changes in the microbiome, particularly those observed in the ELDERMET cohort among residents of long-term care facilities.

Similarly, age-related changes in nutrient intake may also contribute to late-life dysbiosis. It is well-recognized that diet is one of the primary contributors to gut health. Advanced age is associated with deterioration in various aspects of nutrient intake and absorption including dentition, salivary function, digestion, and intestinal transit time [73, 80]. Sensory changes, including taste and smell, may also alter the appetite making certain foods unappealing and thus altering eating habits [81]. It is possible that these changes contribute to dysbiosis though it may be more likely that altered immune responses to “inflammatory” foods among older adults may exacerbate microbial changes.

Another prominent possibility is that chronic activation of the innate and adaptive immune systems due to immunosenescence contributes to an altered bacterial composition in the gut. Such an affect may manifest at least partially due to known increases in hypothalamus-pituitary-adrenal (HPA) axis activity in advanced age [82] as HPA-mediated inflammatory stress responses are known to induce to both immune dysregulation [83] and dysbiosis [84]. Conversely, however, it remains possible—given the known inflammatory effects of dysbiosis—that changes to the microbiome due to other factors (e.g., diet) exacerbate inflammation and altered immunity. Thus, it is presently difficult to decipher the temporal relationship between these changes. Furthermore, this known interplay suggests a tantalizing hypothesis that the processes of immunosenescence and dysbiosis may in fact be interdependent.
Moreover, physical changes to the intestinal epithelial barrier may play a role in dysbiosis and age-related inflammation. Jakobsson et al. previously demonstrated that the composition of the gut microbiota is directly related to the leaky gut [85]. Recent evidence suggests now that intestinal permeability may increase with age. Man et al. [86] recently demonstrated that, compared to younger adults, ileal tissues from older adults demonstrated increased IL-6 concentrations that were accompanied by increased intestinal permeability as a result of elevated claudin-2. These data provide novel evidence from humans indicating the likelihood of a “leaky gut” during advanced age whereby the intestinal barrier preventing harmful substances from reaching the bloodstream is permeated. The leaky gut is well-associated with inflammatory bowel conditions but is now being proposed as a contributor to a wide variety of health conditions [87, 88]—with particular interest in a gut-brain axis which regulates the blood brain barrier [61, 62, 75, 76].

Though somewhat speculative at present, it is possible that the leaky gut is a primary source of inflammation long-observed within the circulation. Studies in Drosophila have reported that age-related changes in the microbiome increase intestinal permeability [89] and drive chronic inflammation [90]. More recently, Thevaranjan et al. [91] were the first to our knowledge to publish work from mammals directly supporting this hypothesis. Using germ-free and conventionally raised mice, this group reported that the germ-free animals did not display an age-related increase in systemic pro-inflammatory cytokines. Moreover, co-housing germ-free with old—but not young—conventionally raised mice increased circulating pro-inflammatory cytokines [91]. Anti-TNF therapy also reversed age-related microbial changes. These data are the strongest to date suggesting the critical role of gut changes in driving age-related inflammation and provide a solid backdrop for continued investigation in this area.

**Potential intervention strategies**

Though additional research is certainly needed in this area, the aforementioned data do suggest that interventions designed to target the gut microbiome may be capable of producing beneficial effects on age-related inflammation and overall health. To date, research on such interventions is as limited as that on the aging microbiome in general. Still, within this small evidence base are some intriguing and promising findings that support the concept of intervening upon the microbiome.

Interestingly, some of the most promising strategies are not truly “gut-specific” but rather well-known interventions which are increasingly recognized to have beneficial effects on the gut microbiome. For instance, dietary habits appear to be one of the biggest drivers of gut health and microbiota composition [92–94]. Specifically, adherence to a high-fat diet commonly seen in Western cultures appears to be one of the driving factors in gut dysbiosis [95, 96]. Accordingly, interventions such as caloric restriction and/or implementing a Mediterranean-style diet may hold promise for balancing the gut microbiome [97, 98]. Moreover, studies exist to suggest potential benefits to specific dietary choices and/or nutritional supplements including (but not necessarily limited to) coffee [99], resveratrol [100], quercetin [100], and/or other polyphenol compounds [101]. Interestingly, many of these strategies have previously been purported to have anti-inflammatory and/or healthy aging properties. These new data suggest that perhaps influences at the level of the gut may be at least partially responsible for these purported benefits. However, studies are needed that specifically evaluate the influence of dietary changes on the gut microbiome and other health parameters among older adults.

Similarly, physical exercise is a clinically recommended intervention with well-established health benefits which is now purported to have important benefits on the gut [102–105]. Recent studies in laboratory animals have demonstrated that aerobic exercise provides a variety of beneficial effects on the gut including enhancing epithelial membrane integrity [106], increasing microbial diversity [106–109], and attenuating intestinal inflammation [106, 110, 111]. However, few human studies in this area have been published to date. Recently, Clarke et al. [112] recently reported that professional athletes (rugby players) displayed a higher diversity of gut microorganisms compared to age-matched controls. However, extensive additional findings from humans—particularly in the form of longitudinal intervention studies—are needed to confirm these beneficial effects. Moreover, to my knowledge, no studies (human or animal) have evaluated the influence of exercise on the gut microbiome in late life. Additionally, questions remain regarding the effects of exercise modality and if these observed effects are specific to aerobic exercise compared to resistance training.

Perhaps not surprisingly, dietary supplementation with probiotics also appears to be among the most promising interventions for re-balancing the gut microbiome. Well-known actions of probiotics include antimicrobial activity, enhancement of intestinal barrier function, and immunomodulation via actions on a wide variety of immune cells [113]. In line with these established mechanisms, studies among older
adults have demonstrated beneficial effects of probiotic preparations on gut microflora composition [114–116] and systemic immunity [116–118]. van Beek et al. also recently reported that 10 weeks of supplementation with the probiotic *Lactobacillus plantarum* WCFS1 prevented age-related decline in the colon mucus barrier in a mouse model of accelerated aging [119]. Probiotics have also been proposed to potentially have anti-inflammatory properties [113]. Such an effect seems plausible given the effects of probiotics on the immune system. To date, several studies have investigated this potential anti-inflammatory affect with the overall effect appearing to be modest [116, 118–122]—though more definitive research in this area is certainly warranted.

More research is also needed regarding the ability to utilize probiotics as a vehicle to deliver other therapeutic compounds. Indeed, genetically modified probiotics have been purported as highly promising treatment strategies [123–125] as they offer a potentially efficacious method to deliver drugs or other therapeutic proteins with precision and a higher degree of site specificity than conventional drug regimens [126]. For instance, Steidler et al. previously reported on the utility of *Lactococcus lactis* as a vehicle for delivering IL-10 for the treatment of inflammatory bowel disease [127]. Elsewhere this strategy has been proposed as a potential method of delivering antihypertensive therapeutics [128, 129]. Given the relative infancy of this field, however, the overall body of literature in this area is sparse.

Future studies are certainly warranted on the potential utility of genetically modified probiotics in the treatment of age-related inflammation and associated diseases.

**Conclusions**

As the population ages across developed nations worldwide, the need for healthcare solutions to ease the burden of age-related diseases grows. Treatments for chronic inflammation represent a particularly promising strategy given the observation of inflammation in “healthy aging” as well as nearly every age-related disorder or disease. Growing evidence indicates that the gut microbiome may represent a novel site of intervention for the prevention and/or treatment of late-life inflammation. A variety of biologic, medical, and lifestyle factors appear to contribute to gut dysbiosis in late-life, and interventions specifically designed to target these factors may be useful in restoring microbial balance and attenuating inflammation (Fig. 3). Still, much remains to be unraveled as it relates to the influence of the gut microbiome on age-related inflammation—particularly as it relates to the potential efficacy of gut-directed interventions. Thus, this field appears to offer great opportunities for aging-related research. I look forward to continued investigation in this area as it has the potential to yield tremendous breakthroughs for improving the health and quality of life of older persons.

---

**Fig. 3** Simplified schematic outlining the potential relationships among health risk factors, gut dysbiosis, inflammation, and age-related disease—as well as potential interventions for attenuating gut-associated inflammation.
Abbreviations
CRP: C-reactive protein; HPA: Hypothalamus-pituitary-adrenal; IL-6: Interleukin 6; IL-8: Interleukin 8; SCFA: Short-chain fatty acids; TLIR: Toll-like receptor; TNF-α: Tumor necrosis factor alpha

Acknowledgments
None

Funding
No funding was necessary to complete the present review.

Availability of data and materials
Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

Author contributions
Dr. Buford is responsible for all aspects of the article.

Ethics approval and consent to participate
Not applicable

Consent for publication
Not applicable

Competing Interests
The author declares that there are no competing interests associated with this manuscript.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 9 May 2017 Accepted: 4 July 2017
Published online: 14 July 2017

References
1. Franceschi C, Motta L, Motta M, Malaguarnera M, Capri M, Vasto S, Candore G, Caruso C, IMUSCE. The extreme longevity: the state of the art in Italy. Exp Gerontol. 2008;43(2):45–52.
2. Troen BR. The biology of aging. Mt Sinai J Med. 2003;70(1):3–22.
3. Candore G, Colonna-Romano G, Balistreri CR, Di Carlo D, Grimaldi MP, Listi F, Nuzzo D, Vasto S, Lio D, Caruso C. Biology of longevity: role of the innate immune system. Rejuvenation Res. 2006;9(1):143–8.
4. Buford TW. Hypertension and aging. Ageing Res Rev. 2016;26:96–111.
5. Cevenini E, Caruso C, Candore G, Capri M, Nuzzo D, Duro G, Rizzo C, Colonna-Romano G, Lio D, Di Carlo D, Palmas MG, Scurti M, Pini E, Franceschi C, Vasto S. Age-related inflammation: the contribution of different organs, tissues and systems. How to face it for therapeutic approaches. Curr Pharm Des. 2010;16(6):609–18.
6. Chung HY, Cesari M, Anton S, Marzetti E, Giovannini S, Seo AY, Carter C, Yu BP, Leeuwenburgh C. Molecular inflammation: up- and down-regulation of aging and age-related diseases. Ageing Res Rev. 2009;8(1):18–30.
7. Singh T, Newman AB. Inflammatory markers in population studies of aging. Ageing Res Rev. 2011;10(3):319–29.
8. Vasto S, Candore G, Balistreri CR, Caruso M, Colonna-Romano G, Grimaldi MP, Listi F, Nuzzo D, Lio D, Caruso C. Inflammatory networks in aging, age-related diseases and longevity. Mech Ageing Dev. 2007;128(1):83–91.
9. Sarkar D, Fisher PB. Molecular mechanisms of aging-associated inflammation. Cancer Lett. 2006;236(1):113–23.
10. Wei J, Xu H, Davies JL. Hemmings GP. Increase of plasma IL-6 concentration with age in healthy subjects. Life Sci. 1992;51(25):1953–6.
11. Ershler WB, Sun WH, Binkley N, Gravenstein S, Volk MJ, Kamoske G, Kloppe RG, Roeker EB, Daynes RA, Weindruch R. Interleukin-6 and aging: blood levels and mononuclear cell production increase with advancing age and in vitro production is modifiable by dietary restriction. Lymphocyte Cytokine Res. 1993;12(4):225–30.
12. Fagiolo U, Costarizza A, Scala E, Fanales-Belasio E, Ortolani C, Cozzi E, Monti D, Franceschi C, Paganeli R. Increased cytokine production in mononuclear cells of healthy elderly people. Eur J Immunol. 1993;23(9):2375–8.
13. Tracy RP, Lemaître RN, Pfty BM, Ives DG, Evans RW, Cushman M, Meilahn EN, Kuller LH. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 1997;17(8):1121–7.
14. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Tracy RP, Rubin SM, Harris TB, Pahor M. Inflammatory markers and cardiovascular disease (The Health, Aging and Body Composition [Health ABC] Study). Am J Cardiol. 2003;92(5):522–8.
15. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB, Pahor M. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation. 2003;108(19):2317–22.
16. Pickup JC, Chunsey GD, Thomas SM, Burt D. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Sci. Med. 2000;7:291–300.
17. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327–34.
18. Beriton AG, Burke GL, Owsusu JA, Carnethon MR, Vaidya D, Barr RG, Jenny NS, Ouyang P, Rotter JI. Inflammation and the incidence of type 2 diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care. 2010;33(4):804–10.
19. Khosla S, Peterson JM, Egan K, Jones JD, Riggs BL. Circulating cytokine levels in osteoporotic and normal women. J Clin Endocrinol Metab. 1994;79(3):707–11.
20. Zheng SX, Vrindts Y, Lopez M, De Groote D, Zangerle PF, Collette J, Franchimont N, Geenen V, Albert A, Regenster J. Increase in cytokine production (IL-1 beta, IL-6, TNF-alpha but not IFN-gamma, GM-CSF or LIF) by stimulated whole blood cells in postmenopausal osteoporosis. Maturitas. 1997;26(1):63–71.
21. Ding C, Parraeswaran V, Udayan R, Burgess J, Jones G. Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study. J Clin Endocrinol Metab. 2008;93(5):1952–8.
22. Yaffe K, Lindquist K, Penninx SBM, Satariano WM, Pahor M, Kritchevsky S, Launer L, Kuller L, Rubin S, Harris T. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology. 2003;61(1):76–80.
23. Weaver JD, Huang MH, Albert M, Harris T, Roe WE, Seeman TE. Interleukin-6 and risk of cognitive decline. MacArthur studies of successful aging. Neurology. 2002;59(3):371–8.
24. Engelhart MJ, Geerlings MJ, Meijer J, Kliian A, Ruitenberg A, van Swieten JC, Stijnjen T, Hofman A, Wittens JCM, Breteker MM. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch Neurol. 2004;61(5):668–72.
25. Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med. 2000;51:245–70.
26. Walston J, McBurnie MA, Newman A, Tracy RP, Kop JW, Hirsch CH, Gottlieiner J, Fried LP. Cardiovascular Health Study. frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study. Arch Intern Med. 2002;162(20):2333–41.
27. Ferrucci L, Pennix BW, Volpato S, Harris TB, Bandeen-Roche K, Balfour J, Leveille SG, Fried LP, MD JM. Change in muscle strength explains accelerated decline of physical function in older women with high interleukin-6 serum levels. J Am Geriatr Soc. 2002;50(12):1947–54.
28. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006;72(1):1605–21.
29. Lu H, Ouyang W, Huang C. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006;72(1):1605–21.
30. Novman AB, Sachs MC, Arnold AM, Fried LP, Komrall R, Cushman M, Pauty BM, Harris TB, Robbins JA, Burke GL, Kuller LH, Lunely T. Total and cause-specific mortality in the cardiovascular health study. J Gerontol A Biol Sci Med Sci. 2009;64(12):6251–61.
73. Claesson MJ, Jeffery IB, Conde S, Power SE, O’Connor BM, Cusack S, Harris HM, Coakley M, Lakshminarayanan B, O’Shea-O’Connor S, Fitzgerald GF, Deane J, O’Connor M, Harnedy N, O’Connor K, O’Mahony D, van Sinderen D, Wallace M, Brennan L, Stanton C, Marchesi JR, Fitzgerald AP, Shanahan F, Hill C, Ross RP, O’Toole PW. Gut microbiota composition correlates with diet and health in the elderly. Nature. 2012;488(7410):178–84.

74. van Tongeren SP, Sluiter JP, Hamms H, Welling GW. Fecal microbiota composition and frailty. Appl Environ Microbiol. 2005;71(10):6438–42.

75. Proctor C, Thienimprimir P, Chattipakorn N, Chattipakorn SC. Diet, gut microbiota and cognition. Metab Brain Dis. 2017;32(1):1–17.

76. Alkaas R, Li J, Li X, Jin M, Zhu B. Human gut microbiota: the links with dementia development. Protein Cell. 2017;8(2):90–102.

77. Blaser MJ, Falkow S. What are the consequences of the disappearing human microbiota? Nat Rev Microbiol. 2009;7(12):887–94.

78. Lee GC, Reveles KR, Atttridge RT, Lawson KA, Mansi IA, Lewis JS,nd, Frei CR. Outpatient antibiotic prescribing in the United States: 2000 to 2010. BMC Med. 2014;12:96-75.

79. Lim CJ, Kong DC, Stuart RL. Reducing inappropriate antibiotic prescribing in the residential care setting: current perspectives. Clin Interv Aging. 2014;9:165–77.

80. Lovat LB. Age related changes in gut physiology and nutritional status. Gut. 1996;38(3):306–9.

81. Fukunaga A, Uematsu H, Sugimoto K. Influences of aging on taste composition of the gut microbiota shapes the colon mucus barrier. EMBO J. 2005;24(18):4697–705.

82. McEwen BS. Protective and damaging effects of stress mediators. N Engl J Med. 1996;338(3):171–9.

83. Bauer ME. Stress, gut endocannabinoids and age of the immune system. Stress. 2005;8(1):169–83.

84. Galley JD, Bailey MT. Impact of stressor exposure on the interplay between commensal microbiota and host inflammation. Gut Microbes. 2014;5(3):390–6.

85. Jakobsson HE, Rodriguez-Pineiro AM, Schutte A, Ermund A, Boysen P, Jakobsson HE, Rodriguez-Pineiro AM, Schutte A, Ermund A, Boysen P. Impact of stressor exposure on the interplay between commensal microbiota and host inflammation. Gut Microbes. 2014;5(3):390–6.

86. Man AL, Bertelli E, Rentini S, Regoli M, Briars G, Marini M, Watson AJ, Galley JD, Bailey MT. Impact of stressor exposure on the interplay between commensal microbiota and host inflammation. Gut Microbes. 2014;5(3):390–6.

87. Nicoletti C. Age-associated modifications of intestinal permeability and innate immunity in human small intestine. Clin Sci (Lond). 2015;129(7):515–27.

88. Nicoletti C. Age-associated modifications of intestinal permeability and innate immunity in human small intestine. Clin Sci (Lond). 2015;129(7):515–27.

89. Bemark M, Sommer F, Backhed F, Hansson GC, Johansson ME. The microbiota: a driving force for chronic disease risk. Curr Opin Clin Nutr Metab Care. 2015;18(5):515–20.

90. De Filippis F, Pellegrini N, Vannini L, Jeffery IB, La Storia A, Laghi L, Serrazzanetti DI, Di Cagno R, Ferricino L, Lazzi C, Turroni S, Coccolin L, Biggdi P, Neviani E, Gobbetti M, O’Toole PW, Ercolini D. High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. Gut. 2016;65(11):1812–21.

91. Oh B, Kim JS, Kweon M, Kim BS, Huh IS. Six-week diet correction for body weight reduction and its subsequent changes of gut microbiota: a case report. Clin Nutr Res. 2016;5(2):137–40.

92. Cowan TE, Palmins MS, Yang J, Bomhof MR, Ardell KL, Reimer RA, Vogel HU, Shearer J. Chronic coffee consumption in the diet-induced obese rat: impact on gut microbiota and serum metabolomics. J Nutr Biochem. 2014;25(4):489–95.

93. Ebenbieria U, Arias N, Boque N, Macanulla MT, Portillo MP, Martinez JA, Milagro FI. Reshaping faecal gut microbiota composition by the intake of trans-resveratrol and quercetin in high-fat sucrose diet-fed rats. J Nutr Biochem. 2015;26(6):651–60.

94. Cardona F, Andres-Lacueva C, Tulipani S, Tinahones FJ, Queipo-Ortuno MI. Benefits of polyphenols on gut microbiota and implications in human health. J Nutr Biochem. 2013;24(8):1415–22.

95. Mika A, Fleschner M. Early-life exercise may promote lasting brain and metabolic health through gut bacterial metabolites. ImmunoCell Biol. 2016;4(4):151–7.

96. Cerda B, Perez M, Perez-Santiago JD, Tomero-Aguilera JF, Gonzalez-Soltero R, Larrosa M. Gut microbiota modification: another piece in the puzzle of the benefits of physical exercise in health? Front Physiol. 2016;7:51.

97. Campbell SC, Winsiewski 2nd PJ. Exercise is a novel promoter of intestinal health and microbial diversity. Expert Rev Gastroenterol Hepatol. 2014;8(5):201–15.

98. Mika A, Fleshner M. Early-life exercise may promote lasting brain and metabolic health through gut bacterial metabolites. ImmunoCell Biol. 2016;4(4):151–7.

99. O’Sullivan O, Cronin O, Clarke SF, Murphy EF, Molloy MG, Shanahan F, Cotter PD. Exercise and the microbiota. Gut Microbes. 2015;6(2):131–6.

100. Campbell SC, Winsiewski PJ, Noji M, McGuinness LR, Haggblom MM, Littlefoot SA, Joseph LB, Kerkhof LJ. The effect of diet and exercise on the intestinal integrity and microbial diversity in mice. PLoS One. 2016;11(3):e0150502.

101. Allen JM, Berg Miller ME, Pence BD, Whitlock K, Nehra V, Gaskins HR, White BA, Fryer JD, Woods JA. Voluntary and forced exercise differentially alters the gut microbiome in C57BL/6j mice. J Appl Physiol (1985). 2015;118(8):1059–66.

102. Evans CC, LePard KJ, Kwak JW, Stancukas MC, Laskowski S, Dougherty J, Moulton L, Giaele A, Wang Y, Leone V, Antonopoulos DA, Smith D, Chang SB, & Ciancio MJ. Exercise prevents weight gain and alters the gut microbiota in a mouse model of high fat diet-induced obesity. PLoS One. 2014;9(3):e92193.

103. Mika A, Van Treuren W, Gonzalez A, Herrera JJ, Knight R, Fleschner M. Exercise is more effective at altering gut microbial composition and producing stable changes in lean mass in juvenile versus adult male F344 Rats. PLoS One. 2015;10(5):e0125889.

104. Hoffmann-Goetz L, Pavenza N, Packer N, Guan J. Freewheel training decreases pre- and increases anti-inflammatory cytokine expression in mouse intestinal lymphocytes. Brain Behav Immun. 2010;24(7):1105–15.

105. Hoffmann-Goetz L, Pavenza N, Guan J. Voluntary exercise training in mice increases the expression of antioxidant enzymes and decreases the expression of TNF-alpha in intestinal lymphocytes. Brain Behav Immun. 2009;23(4):498–506.

106. Clarke SF, Murphy EF, O’Sullivan O, Lucey AJ, Murphy EF, Molloy MG, Shanahan F, Cotter PD. Exercise and the microbiota. Gut Microbes. 2015;6(2):131–6.

107. N. Shearer J. Chronic coffee consumption in the diet-induced obese rat: impact on gut microbiota and serum metabolomics. J Nutr Biochem. 2014;25(4):489–95.

108. Ng SC, Hart AL, Kamm MA, Stagg AJ, Knight SC. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis. 2009;15(2):300–10.

109. Ahmed M, Prasad J, Gill H, Stevenson L, Gopal P. Impact of consumption of different levels of Bifidobacterium lactis HN019 on the intestinal microflora of elderly human subjects. J Nutr Health Aging. 2007;11(1):26–31.

110. Rampelli S, Candela M, Severgnini M, Biagi E, Turroni S, Roselli M, Canevali P, Donini L, Biggdi P. A probiotics-containing biscuit modulates the intestinal microbiota in the elderly. J Nutr Health Aging. 2013;17(2):166–72.

111. Liu Y, Gibson GR, Walton GE. An in vitro approach to study effects of prebiotics and probiotics on the faecal microbiota and selected immune parameters relevant to the elderly. PLoS One. 2016;11(9):e0162604.
117. Gill HS, Rutherford KJ, Cross ML, Gopal PK. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium lactis HNO19. Am J Clin Nutr. 2001;74(6):833–9.

118. Moro-Garcia MA, Alonso-Arias R, Baltadjeva M, Fernandez Benitez C, Fernandes Bantial MA, Diaz Ruiz Sanchez E, Alonso Santos R, Alvarez Sanchez M, Saevedra Mijan J, Lopez-Larea C. Oral supplementation with Lactobacillus delbrueckii subsp. bulgaricus 8481 enhances systemic immunity in elderly subjects. Age (Dordr). 2013;35(4):1311–26.

119. van Beek AA, Sovran B, Hugenholzt F, Meijer B, Hoogerland JA, Mihaliova V, van der Ploeg C, Belzer C, Boekschoten MV, Hoeijmakers JH, Vermeij WP, de Vos P, Wells JM, Leenen PJ, Nicolle C, Hendriks RW, Savelkoul HF. Supplementation with Lactobacillus plantarum WCE51 Prevents Decline of Mucus Barrier in Colon of Accelerated Aging Ercc1−/Δelta7 Mice. Front Immunol. 2016;7:408.

120. Valentini L, Pinto A, Bourdel-Marchasson I, Ostan R, Brigidi P, Turnoni S, Hrelia S, Hrelia P, Beresswill S, Fischer A, Leoncini E, Malaguti M, Blanc-Bisson C, Durieu J, Spazzafumo L, Buccolini F, Pryen F, Donini LM, Franceschi C, Lochs H. Impact of personalized diet and probiotic supplementation on in inflammation, nutritional parameters and intestinal microbiota-The “RISTOMED project”: randomized controlled trial in healthy older people. Clin Nutr. 2015;34(4):593–602.

121. Ostan R, Bene MC, Spazzafumo L, Pinto A, Donini LM, Pryen F, Charron Z, Valentini L, Lochs H, Bourdel-Marchasson I, Blanc-Bisson C, Buccolini F, Brigidi P, Franceschi C, d’Alessio PA. Impact of diet and nutraceutical supplementation on inflammation in elderly people: results from the RISTOMED study, an open-label randomized control trial. Clin Nutr. 2016;35(4):812–8.

122. Akbari E, Asemi Z, Daneshvar Kakhaki R, Bahmani F, Kouchaki E, Tamtaji OR, Hamidi GA, Salami M. Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer’s disease: a randomized, double-blind and controlled trial. Front Aging Neurolsci. 2016;8:256.

123. Steidler L. Genetically engineered probiotics. Best Pract Res Clin Gastroenterol. 2003;17(5):861–76.

124. Syvanen M. Churning out safer microbes for drug delivery. Nat Biotechnol. 2003;21(7):758–9.

125. Paton AW, Morona R, Paton JC. Bioengineered microbes in disease therapy. Trends Mol Med. 2012;18(7):417–25.

126. Kumar M, Yadav AK, Verma V, Singh B, Mal G, Nagpal R, Hemalatha R. Bioengineered probiotics as a new hope for health and diseases: an overview of potential and prospects. Future Microbiol. 2016;11(4):585–600.

127. Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B, Remon JP, Remaut E. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol. 2003;21(7):785–9.

128. Daliri EB, Lee BH, Oh DH. Current Perspectives on Antihypertensive Probiotics. Probiotics Antimicrob Proteins. 2016.

129. Yang G, Jiang Y, Yang W, Du F, Yao Y, Shi C, Wang C. Effective treatment of hypertension by recombinant Lactobacillus plantarum expressing angiotensin converting enzyme inhibitory peptide. Microb Cell Fact. 2015;14:202-015-0394-2.

130. Hopkins MJ, Macfarlane GT. Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. J Med Microbiol. 2002;51(5):448–54.

131. Hayashi H, Sakamoto M, Kitahara H, Benno Y. Molecular analysis of fecal microbiota in elderly individuals using 16S rDNA library and T-RFLP. Microbiol Immunol. 2003;47(8):557–70.

132. Woodmansey EJ, McMurdie ME, Macfarlane GT, Macfarlane S. Comparison of compositions and metabolic activities of fecal microbiota in young adults and in antibiotic-treated and non-antibiotic-treated elderly subjects. Appl Environ Microbiol. 2004;70(10):6113–22.

133. Odamaki T, Kato K, Sugahara H, Hashikura N, Takahashi S, Xiao JZ, Abe F, Osawa R. Age-related changes in gut microbiota composition from newborn to centenarian: a cross-sectional study. BMC Microbiol. 2016;16:9-016-0708-5.